Abstract
The rising cost of pharmaceuticals has been an issue of growing concern in many countries both developing and developed. In the United States, high pharmaceutical prices cause significant financial stress to patients and create barriers to access, causing treatable conditions to deteriorate. Many legislative attempts have been attempted on various levels to control prices, but in the United States it has been mostly left to states to address the issue. In this comparative case study, pharmaceutical utilization data and sentiment data are analyzed from three states to represent various approaches: South Dakota to represent states with little legislation, Rhode Island to represent states with average amounts of legislation, and New Jersey to represent states with high levels of legislation. This analysis will provide insight into whether current legislative efforts being undertaken at the state level are proving to be sufficient to tackle an ongoing and worsening problem.
Library of Congress Subject Headings
Drugs--Prices--United States; Pharmaceutical policy--United States--States--Evaluation; Drugs--Law and legislation--United States--States--Evaluation
Publication Date
3-28-2022
Document Type
Thesis
Student Type
Graduate
Degree Name
Science, Technology and Public Policy (MS)
Department, Program, or Center
Public Policy (CLA)
Advisor
Eric Hittinger
Advisor/Committee Member
Qing Miao
Advisor/Committee Member
Iris Asllani
Recommended Citation
Williams, Braedon, "An Analysis of State Level Legislation Aimed at Reducing Pharmaceutical Prices: Are They Enough?" (2022). Thesis. Rochester Institute of Technology. Accessed from
https://repository.rit.edu/theses/11186
Campus
RIT – Main Campus
Plan Codes
STPP-MS